Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Clinical Research and Equipment Industry Analysis
UpdatedApr 26, 2026
DataAggregated Company Financials
Companies11
- 7D1.8%
- 3M2.1%
- 1Y6.2%
- YTDn/a
The Clinical Research and Equipment industry is up 1.8% in the last week, with Locus Cell up 19%. Meanwhile, EirGenix actually underperformed within the industry, shrinking 9.9% in the last week. This takes the industry's 12 month performance to a gain of 6.2%.
Industry Valuation and Performance
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 27 Apr 2026 | NT$35.3b | NT$2.5b | -NT$767,980,000.00 | 21.9x | -46x | 14.1x |
| Wed, 25 Mar 2026 | NT$31.6b | NT$2.5b | -NT$747,966,000.00 | 20.6x | -42.3x | 12.6x |
| Fri, 20 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.8x | -48.3x | 13.7x |
| Sun, 18 Jan 2026 | NT$35.0b | NT$2.4b | -NT$689,929,000.00 | 25.4x | -50.7x | 14.4x |
| Tue, 16 Dec 2025 | NT$35.2b | NT$2.4b | -NT$670,921,000.00 | 22.5x | -52.5x | 14.4x |
| Thu, 13 Nov 2025 | NT$36.0b | NT$2.5b | -NT$871,098,000.00 | 19x | -41.4x | 14.6x |
| Sat, 11 Oct 2025 | NT$38.0b | NT$2.5b | -NT$870,437,000.00 | 19x | -43.6x | 15.5x |
| Mon, 08 Sep 2025 | NT$35.9b | NT$2.5b | -NT$819,216,000.00 | 20.4x | -43.8x | 14.6x |
| Wed, 06 Aug 2025 | NT$33.8b | NT$2.5b | -NT$600,003,000.00 | 20.7x | -56.3x | 13.7x |
| Fri, 04 Jul 2025 | NT$34.0b | NT$2.5b | -NT$600,003,000.00 | 23.2x | -56.6x | 13.8x |
| Sun, 01 Jun 2025 | NT$33.7b | NT$2.5b | -NT$600,003,000.00 | 22.7x | -56.2x | 13.7x |
| Tue, 29 Apr 2025 | NT$31.4b | NT$2.5b | -NT$540,128,000.00 | 24x | -58.1x | 12.7x |
| Thu, 27 Mar 2025 | NT$36.6b | NT$2.4b | -NT$560,979,000.00 | 29.5x | -65.2x | 15.2x |
| Sat, 22 Feb 2025 | NT$37.4b | NT$2.6b | -NT$854,432,000.00 | 24.3x | -43.8x | 14.6x |
| Mon, 20 Jan 2025 | NT$37.1b | NT$2.6b | -NT$854,432,000.00 | 23.2x | -43.4x | 14.5x |
| Wed, 18 Dec 2024 | NT$35.6b | NT$2.6b | -NT$854,432,000.00 | 24.8x | -41.7x | 13.9x |
| Fri, 15 Nov 2024 | NT$41.2b | NT$2.5b | -NT$712,402,000.00 | 24.1x | -57.8x | 16.4x |
| Sun, 13 Oct 2024 | NT$40.7b | NT$2.3b | -NT$836,610,000.00 | 22.1x | -48.7x | 17.9x |
| Tue, 10 Sep 2024 | NT$40.5b | NT$2.3b | -NT$836,610,000.00 | 22.6x | -48.4x | 17.8x |
| Thu, 08 Aug 2024 | NT$39.1b | NT$2.1b | -NT$797,765,000.00 | 30.4x | -49x | 18.3x |
| Sat, 06 Jul 2024 | NT$44.7b | NT$2.1b | -NT$797,765,000.00 | 34.5x | -56.1x | 21x |
| Mon, 03 Jun 2024 | NT$41.0b | NT$2.1b | -NT$797,765,000.00 | 32.4x | -51.4x | 19.2x |
| Wed, 01 May 2024 | NT$40.0b | NT$2.1b | -NT$914,899,000.00 | 32.2x | -43.7x | 18.8x |
| Fri, 29 Mar 2024 | NT$40.5b | NT$2.1b | -NT$903,875,000.00 | 31.5x | -44.8x | 19.2x |
| Sun, 25 Feb 2024 | NT$43.6b | NT$2.1b | -NT$610,218,000.00 | 33x | -71.5x | 21x |
| Tue, 23 Jan 2024 | NT$44.7b | NT$2.1b | -NT$610,218,000.00 | 33x | -73.2x | 21.5x |
| Thu, 21 Dec 2023 | NT$48.0b | NT$2.1b | -NT$610,218,000.00 | 34.4x | -78.7x | 23.1x |
| Sat, 18 Nov 2023 | NT$48.9b | NT$2.1b | -NT$592,912,000.00 | 25.1x | -82.4x | 23.5x |
| Mon, 16 Oct 2023 | NT$47.7b | NT$2.2b | -NT$497,769,000.00 | 31.1x | -95.8x | 21.4x |
| Wed, 13 Sep 2023 | NT$43.2b | NT$2.2b | -NT$497,769,000.00 | 31x | -86.8x | 19.4x |
| Fri, 11 Aug 2023 | NT$44.4b | NT$2.3b | -NT$479,239,000.00 | 43x | -92.6x | 19.6x |
| Sun, 09 Jul 2023 | NT$48.8b | NT$2.5b | -NT$274,767,000.00 | 42.7x | -177.6x | 19.9x |
| Tue, 06 Jun 2023 | NT$49.7b | NT$2.5b | -NT$274,706,000.00 | 42.9x | -180.9x | 20.3x |
| Thu, 04 May 2023 | NT$49.4b | NT$2.7b | -NT$29,017,000.00 | 24.1x | -1701.9x | 18.6x |
Price to Earnings Ratio
-1701.9x
Current Industry PE
- Investors are pessimistic on the Taiwanese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 17.1x is higher than the industry's current PS ratio of 14.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Revenues have also declined 2.0% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 5.44% | |
| Healthcare | -3.12% | |
| Life Sciences | 1.78% | |
| Clinical Research and Equipment | 1.78% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6891 Locus Cell | NT$61.00 | 19.4% +NT$2.0b | 177.9% | PS958x | |
| 6986 HeXun Biosciences | NT$63.40 | 4.3% +NT$119.6m | -16.5% | PE26.1x | |
| 7837 Creative Life Science | NT$110.00 | 3.3% +NT$78.3m | n/a | n/a | |
| 6939 TFBS Bioscience | NT$21.10 | 4.2% +NT$29.7m | -15.9% | n/a |